How to Appeal a Cigna Prior-Authorization Denial for Weight-Loss Medication

By the PriorAuthAppeal editorial team · Sources cited · Independent of Cigna

Last reviewed 2026-05-06

Cigna covers Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3 mg), and Zepbound (tirzepatide) under its Drug and Biologic Coverage Policy: Weight Loss Pharmacotherapy when a patient meets four simultaneous requirements: a qualifying BMI, documented participation in a structured weight-loss program for at least six months, no specific contraindications, and a commitment to concurrent lifestyle modification. If Cigna denied your request, this guide walks through exactly what the policy requires, why denials happen, and how to build an appeal that speaks directly to each gap Cigna identified.

At a Glance

• Covered drugs: Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3 mg), Zepbound (tirzepatide)
• BMI threshold: BMI ≥ 30 with no comorbidity required, OR BMI ≥ 27 with at least one recognized weight-related comorbidity
• Recognized comorbidities: Type 2 Diabetes, Prediabetes, Hypertension, Dyslipidemia, Obstructive sleep apnea, Cardiovascular disease
• Step-therapy / lifestyle requirement: 6 months of documented participation in a structured weight-loss program within the past 2 years (commercial program, medical weight-loss clinic, registered dietitian, or supervised lifestyle program) PLUS concurrent reduced-calorie diet and ongoing physical activity during therapy
• Contraindications that disqualify: Personal or family history of medullary thyroid carcinoma, MEN-2, severe gastroparesis, or pancreatitis
• Reauthorization trigger: After 12 weeks of therapy, at least 5% reduction from baseline weight must be documented; annual reauthorization required thereafter
• Appeal deadline: 180 days from the denial date
• Internal appeal levels: 2
• External review: Available

How Cigna Decides Whether to Cover GLP-1 Medications

Cigna evaluates every prior-authorization request for these medications against four criteria that must all be satisfied at the same time. Missing even one is enough for a denial, which is why understanding each requirement precisely matters.

BMI and comorbidity. The patient must be an adult aged 18 or older with a BMI of 30 or higher. Patients with a BMI between 27 and 29.9 are also eligible, but only if they have at least one documented weight-related comorbidity from Cigna's recognized list: Type 2 Diabetes, Prediabetes, Hypertension, Dyslipidemia, Obstructive sleep apnea, or Cardiovascular disease. BMI must be documented in a recent clinical note — a number entered in a problem list without a corresponding measurement date is often insufficient.

Structured weight-loss program history. This is the criterion that catches the most patients off guard. Cigna requires documented participation in a structured weight-loss program for at least six months within the past two years. The program can be a commercial weight-loss program (such as Weight Watchers or Jenny Craig), a medical weight-loss clinic, visits with a registered dietitian, or a supervised lifestyle program. The key word is "documented" — your physician needs records that show attendance or participation, not just a note that you "attempted diet and exercise."

No contraindications. Cigna will deny the request if the patient or an immediate family member has a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN-2), or if the patient has a history of severe gastroparesis or pancreatitis. These are also FDA black-box or precautionary contraindications for the GLP-1 drug class itself, so a denial on this basis is unlikely to be overturned without strong medical documentation clarifying the specific diagnosis.

Concurrent lifestyle modification. Approval is contingent on the patient committing to a reduced-calorie diet and increased physical activity throughout the entire treatment period — not just at initiation. For reauthorization, Cigna requires documented weight loss of at least 5% from baseline after 12 weeks, plus annual reauthorization with evidence of continued weight maintenance.

What Makes Cigna's Policy Distinct from Other Insurers

Cigna's GLP-1 policy has three features that set it apart from the industry standard and that patients and physicians frequently underestimate.

A strict two-year lookback window for the lifestyle program. Many insurers require documentation of a prior weight-loss attempt but do not anchor that requirement to a specific timeframe. Cigna explicitly requires the six-month structured program to have occurred within the past two years. A patient who completed a medically supervised program three years ago — even with strong results — will not satisfy this criterion and must restart or find more recent documentation. This is a harder standard than most commercial plans impose, and it catches patients who believe their prior history "counts."

The 12-week, 5% weight-loss reauthorization gate. Cigna builds a mid-therapy checkpoint into its coverage structure that is not universal across insurers. At the 12-week mark, the patient must demonstrate at least a 5% reduction from their baseline weight or coverage can be suspended pending reauthorization. This aligns roughly with the FDA-labeled efficacy benchmarks for GLP-1 agents, but it creates a practical risk: patients who start at a higher dose and are still titrating upward at week 12 may not yet have reached their therapeutic dose, let alone the 5% threshold. Physicians should document titration schedules and expected dose-response timelines to contextualize early weigh-ins.

No explicit step-therapy requiring a prior failed medication. Unlike some insurers who require a documented trial of an older weight-loss drug (such as phentermine/topiramate or orlistat) before approving a GLP-1, Cigna's policy as written does not list a pharmacologic step-therapy requirement. The required "step" is the six-month lifestyle program, not a prior drug trial. This is actually a patient-favorable aspect of Cigna's criteria — but physicians unfamiliar with the policy sometimes preemptively document a failed drug trial that isn't required, wasting time.

The Most Common Reasons Cigna Denies These Requests

Cigna issues denials under three primary codes. Knowing which code appeared on your Explanation of Benefits (EOB) — the document that explains how your claim was processed — tells you which gap to address first.

• CO-50 (not medically necessary): This is the most common denial code. It usually means the prior-authorization submission didn't demonstrate all four coverage criteria, most often the lifestyle program documentation or the BMI/comorbidity pairing.
• N-130 (plan limitation): This code indicates the specific benefit plan the patient is enrolled in excludes or limits weight-loss medications. This is a distinct problem from a medical-necessity denial and requires a different appeal strategy (see below).
• N-455 (missing documentation): The submission was incomplete — records were absent, illegible, or didn't cover the required timeframe. This is the most straightforwardly fixable denial type.

How to Address Each Denial Reason

For CO-50 (not medically necessary), the appeal must affirmatively demonstrate each of Cigna's four criteria with primary source documentation. That means a physician note with a measured BMI or weight, an ICD-10 code and clinical note for any comorbidity, records from the structured weight-loss program with dates spanning at least six months within the past two years, and a treatment plan or attestation confirming concurrent lifestyle modification. Supporting this with clinical guideline citations — specifically the AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity (Garvey et al., Endocrine Practice, 2023) and the American Diabetes Association Standards of Care 2025 Section 8 — demonstrates that the prescribing decision reflects published expert consensus, not physician preference alone.

For N-130 (plan limitation), the first step is confirming whether the exclusion is a hard plan exclusion or a benefit limit that can be waived. Request the Summary Plan Description (SPD) and the Evidence of Coverage (EOC) document from your employer's HR department or from Cigna directly. If the plan is an employer-sponsored ERISA plan, the plan administrator is required under ERISA Section 503 (29 CFR 2560.503-1) to provide a full explanation of the benefit limitation and the basis for applying it. If the plan is an ACA marketplace plan, ACA Section 1557's nondiscrimination provisions may be relevant if the exclusion disproportionately affects patients with a recognized medical condition.

For N-455 (missing documentation), compile the specific records that were missing and resubmit. A covering letter that itemizes each document and maps it to the specific coverage criterion it satisfies makes the reviewer's job easier and reduces the chance of a second denial on the same grounds.

Federal and State Laws That Protect Your Right to Appeal

Two federal frameworks give you enforceable appeal rights regardless of which state you live in.

ERISA Section 503 (29 CFR 2560.503-1) applies to employer-sponsored health plans. It requires the plan to provide a written explanation of every denial that includes the specific reason, the plan provision relied upon, and a description of available review procedures. It also sets minimum timelines: the plan must decide a first-level internal appeal within 60 days for non-urgent claims. If the plan violates these procedural requirements, the denial itself may be challengeable on procedural grounds.

ACA Section 1557 prohibits discrimination in health programs receiving federal financial assistance. If you believe your plan's coverage exclusion or denial reflects discriminatory treatment based on a health condition (obesity is increasingly recognized clinically as a chronic disease, not a lifestyle choice — a position explicitly supported by the AACE/ACE 2023 guidelines), this provision provides a basis for a formal complaint with the U.S. Department of Health and Human Services Office for Civil Rights.

After exhausting two levels of internal appeal, you have the right to request an independent external review under ACA Section 2719. An independent review organization (IRO) evaluates the denial without deference to Cigna's original decision. Cigna's policy confirms external review is available, and IRO decisions in favor of patients are binding on the insurer.

What a Strong Appeal Letter Contains

A Cigna GLP-1 appeal letter that addresses the common denial reasons should include every item below.

• Patient's full name, date of birth, Cigna member ID, and the specific drug name denied
• The denial date and the denial code (CO-50, N-130, or N-455) from the EOB
• A statement of the specific coverage criteria from Cigna's Drug and Biologic Coverage Policy: Weight Loss Pharmacotherapy, followed by evidence satisfying each one
• Physician-signed clinical notes documenting measured BMI, diagnosis of any comorbidity with ICD-10 code, and treatment rationale
• Records from the structured weight-loss program showing participation dates (must span at least 6 months within the past 2 years)
• A physician attestation that the patient is committed to concurrent reduced-calorie diet and physical activity
• At least one citation to the AACE/ACE 2023 Guidelines or ADA Standards of Care 2025 Section 8 establishing GLP-1 therapy as evidence-based treatment
• A request for the specific basis of the denial under 29 CFR 2560.503-1 if not already provided
• A clear closing sentence requesting reversal and approval of the prior authorization

Timeline: What Happens After You Submit Your Appeal

You have 180 days from the denial date to file your first internal appeal with Cigna — do not let this deadline pass.

• First internal appeal decision: Cigna must respond within 30 days for pre-service (prior authorization) appeals
• Second internal appeal: If the first appeal is denied, you may escalate to Cigna's second internal review level; the same 30-day decision timeline applies
• External review request: After both internal levels are exhausted, submit a written request for independent external review; the IRO has 45 days to issue a binding decision on standard reviews (expedited review — for urgent situations — must be decided within 72 hours)
• File a complaint: If Cigna misses its own timelines or fails to provide required documentation, you can file a complaint with your state insurance commissioner or, for ERISA plans, with the U.S. Department of Labor's Employee Benefits Security Administration (EBSA)

Frequently Asked Questions About Cigna GLP-1 Appeals

Does Cigna require me to try a different weight-loss drug before approving a GLP-1?

Cigna's Weight Loss Pharmacotherapy policy does not include a step-therapy requirement for a prior failed medication — the required prior step is a six-month structured lifestyle program, not a pharmacologic trial. Some physicians assume a phentermine or orlistat trial is needed; it is not listed in Cigna's criteria. If your denial letter cites a failure to try another drug, request the specific plan provision in writing under 29 CFR 2560.503-1, because that requirement is not reflected in the published coverage policy.

My BMI is 28 and I have prediabetes — does Cigna cover these medications for me?

Yes, a BMI of 27 or higher combined with at least one recognized comorbidity — and Prediabetes is explicitly on Cigna's recognized list — satisfies the BMI threshold criterion. The key is that your physician's note must document both the BMI measurement and the prediabetes diagnosis with an ICD-10 code; a verbal mention in a visit summary is not sufficient. The ADA Standards of Care 2025 Section 8 also supports GLP-1 use in patients with prediabetes, which strengthens a medical-necessity argument.

I completed a Weight Watchers program four years ago. Does that count toward the 6-month requirement?

No — Cigna's policy requires the structured weight-loss program to have occurred within the past two years. A program completed four years ago does not satisfy the lookback window, even if it was six months or longer. You would need to document a more recent program or initiate one now and request a resubmission once you have qualifying participation records. A registered dietitian engagement that started within the past two years would qualify if documented with visit dates.

What happens if I don't lose 5% of my body weight by week 12 on the medication?

Cigna can require reauthorization and may decline to continue coverage if the 5% threshold is not met at 12 weeks. If you are still in the dose-titration phase at that point, your physician should proactively document that you have not yet reached the full therapeutic dose and that clinical guidelines — specifically the AACE/ACE 2023 Guidelines — recognize that full weight-loss response typically emerges at maintenance dosing, not during titration. This clinical context does not guarantee continued approval but directly addresses the insurer's framework for evaluating early response.

Can I appeal if my employer's plan simply excludes weight-loss drugs entirely?

You can and should still appeal, though a hard plan exclusion (denial code N-130) is the most difficult category to overturn. Start by requesting the full Summary Plan Description and confirming the exact language of the exclusion under ERISA Section 503. Then determine whether the exclusion contains any carve-outs for medical necessity or specific diagnoses — some plans that exclude "weight loss" drugs still cover GLP-1 agents when prescribed for Type 2 Diabetes or cardiovascular risk reduction. If the plan is an ACA marketplace plan rather than an employer ERISA plan, ACA Section 1557 nondiscrimination protections may provide additional leverage.

What does the external review process actually decide, and is it binding on Cigna?

An independent review organization (IRO) conducts a de novo review — meaning it looks at your case fresh, without deferring to Cigna's original determination — and issues a decision that is legally binding on Cigna if it rules in your favor. External review is available after both internal appeal levels are exhausted. The IRO panel typically includes board-certified physicians in relevant specialties. Submitting clinical guideline citations (AACE/ACE 2023, ADA 2025) with your external review request gives the panel the clinical framework to evaluate whether Cigna's denial aligns with current standard of care.

Get a Physician-Ready Appeal Letter in 30 Minutes

Building a complete, citation-backed appeal letter while managing a denial is genuinely stressful — and the difference between a vague letter and a precise one often determines the outcome. PriorAuthAppeal ($59, with a money-back guarantee if your physician declines to sign) generates a customized letter that maps your specific documentation to Cigna's exact coverage criteria, incorporates the relevant guideline and statute citations, and is formatted for immediate physician review and signature. That said, every section of this guide is designed to be fully actionable on its own — the criteria, the denial codes, the timelines, and the statutory protections are all here whether or not you use any paid service. The goal is to make sure Cigna hears the strongest possible version of your case.